CagriSema vs Selank
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Selank
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia for anxiety and cognitive enhancement.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Selank |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Modulates the expression of brain-derived neurotrophic factor (BDNF) and affects serotonin and norepinephrine systems. Has immunomodulatory and anxiolytic properties. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Intranasal administration: 250-500mcg 2-3 times daily. Subcutaneous: 250-500mcg daily. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Most commonly administered intranasally for cognitive effects. Can also be injected subcutaneously. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Generally well-tolerated. Some users report mild fatigue or nasal irritation with intranasal use. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Selank:
Detailed Analysis
Commonalities
CagriSema and Selank are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Selank for Cognitive Performance.
Ready to Learn More?
Looking for trusted sources?